INNNOVAX is also marketed as INNOFUSION and FUSION in some markets. Check with your Merck/MSD Animal Health representative regarding the products available for your area.
INNOVAX-ND is a frozen, live, cell-associated vaccine that provides proven prevention against Newcastle disease (ND) and Marek’s disease (MD). It is approved for in ovo administration for 18-day embryos and by subcutaneous vaccination for healthy 1-day-old chickens. The duration of immunity for both vaccines has been shown to be at least 60 weeks.
The foundation of the vaccine is the herpesvirus of turkey (HVT), which is known to be safe for chickens and is an aid in the prevention of MD. Antigens from Newcastle disease virus have been inserted to help prevent ND.
INNOVAX ND-SB is the same vaccine as INNOVAX-ND, but has the addition of the SB1 serotype, which provides lifelong prevention against very virulent MD.
INNOVAX-ND and INNOVAX-ND-SB reduce the risk of respiratory reactions, the spread of live virus in the environment and interference with IB vaccines.
INNOVAX-ND and INNOVAX-ND-SB:
- Provide extended protection for virulent ND and MD
- Offer effective protection in the face of ND virus maternal antibodies
- Replace a conventional live ND vaccination program when exotic ND is not present
- Remove the potential for respiratory reactions due to live ND vaccines
- Allow the use of monovalent infectious bronchitis (IB) vaccines, improving IB protection
Both vaccines replace oil-based inactivated ND emulsions and live ND vaccines applied at the hatchery or in the field. The water-based diluent in INNOVAX vaccines reduces injection risks to chicks and operators compared to oil-based emulsions. Live ND vaccines may not be needed, but if the challenge is deemed to be very severe, they may still be applied in the hatchery. Subsequent vaccinations with live ND vaccines in the field are not necessary.
- INNOVAX®-ND Product Bulletin for Serotypes 2&3 (pdf, 238 KB)
- INNOVAX®-ND Product Bulletin for Serotype 3 (pdf, 406 KB)
- INNOVAX-ND-SB ad (pdf, 1,354 KB)
- INNOVAX-ND-SB Q&A (pdf, 893 KB)
- INNOVAX Vaccines (pdf, 175 KB)